- Record: found
- Abstract: found
- Article: not found
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Lecia V Sequist
1 ,
Renato G Martins ,
David Spigel ,
Steven M Grunberg ,
Alexander Spira ,
Pasi A Jänne ,
Victoria A Joshi ,
David McCollum ,
Tracey L Evans ,
Alona Muzikansky ,
Georgiana L Kuhlmann ,
Moon Han ,
Jonathan S Goldberg ,
Jeffrey Settleman ,
A John Iafrate ,
Jeffrey A Engelman ,
Daniel A Haber ,
Bruce E Johnson ,
Thomas J Lynch
May 20 2008
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms.